Lori Travis
Neurology · Phoenix, AZNPI 1093794885
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2019 at $157,011 and has fallen 80.1% since, to $31,204 in 2025. Among neurology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,593 payments — averaging $254.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$96K
- EMD Serono, Inc.$83K
- Mallinckrodt Hospital Products Inc.$62K
- Biogen$59K
- Novartis$23K
- Bristol Myers Squibb$19K
- plus $64K from 44 others
Across 135 payments — averaging $8110.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$552K
- Novartis$379K
- Roche Products Limited$108K
- Bristol Myers Squibb$56K
What the payments were for
- Consulting fees$135,50733%
- Speaking & faculty fees$211,92652%
- Grants$4,0001%
- Travel & lodging$21,0595%
- Food & beverage$31,9988%
- Education$1,0240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$405,514 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 39 | $398,634 |
| BafiertamMonomethyl Fumarate | 28 | $230,248 |
| Kesimpta PenOfatumumab | 19 | $212,179 |
| CopaxoneGlatiramer Acetate | 26 | $146,521 |
| AmpyraDalfampridine | 14 | $73,281 |
| Nurtec OdtRimegepant Sulfate | 23 | $51,353 |
| Teriflunomide | 36 | $38,777 |
| GlatopaGlatiramer Acetate | 14 | $22,766 |
| Emgality PenGalcanezumab-Gnlm | 28 | $19,697 |
| QuliptaAtogepant | 16 | $17,056 |
| RytaryCarbidopa/Levodopa | 12 | $15,405 |
| Ajovy SyringeFremanezumab-Vfrm | 11 | $7,714 |
| Dalfampridine ErDalfampridine | 25 | $5,893 |
| Levetiracetam | 67 | $2,353 |
| Primidone | 34 | $2,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $95,706 | $398,63439 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $10,889 | $146,52126 claims |
| Acorda Therapeutics, IncAmpyra | $661 | $73,28114 claims |
| PfizerNurtec Odt | $140 | $51,35323 claims |
| AbbVieQulipta | $1,449 | $17,05616 claims |
| Amneal Pharmaceuticals LLCRytary | $532 | $15,40512 claims |
| Upsher-smith Laboratories LLCTopiramate | $71 | $22218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
- Joshua TobinPhoenix$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.